Toshiyuki Yoneda Selected Research

Neoplasm Metastasis (Metastasis)

09/2008	Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases.
11/2006	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
02/2006	Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
09/2005	Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
07/2004	Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
10/2003	Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
10/2003	Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model.
08/2003	C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
10/2002	Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia.
10/2002	The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
05/2002	[Role of cell adhesion molecules in bone metastasis]
03/2002	Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice.
02/2002	Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.

Articles by Research Topic

Disease

13	Neoplasm Metastasis (Metastasis) 09/2008 - 02/2002
12	Breast Neoplasms (Breast Cancer) 09/2008 - 02/2002
2	Bone Resorption 01/2006 - 03/2002
2	Neoplasms (Cancer) 08/2003 - 02/2002
1	Metabolic Bone Diseases (Osteopenia) 08/2006
1	Melanoma (Melanoma, Malignant) 02/2005
1	Tissue Adhesions 08/2003
1	Hypercalcemia (Milk Alkali Syndrome) 10/2002
1	Carcinoma (Carcinomatosis) 10/2002
1	Lung Neoplasms (Lung Cancer) 03/2002

Drug/Important Bio-Agent (IBA)

2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2006 - 08/2003
2	CortactinIBA 05/2006 - 01/2006
2	zoledronic acid (zoledronate)FDA Link 07/2004 - 10/2003
1	OsteoprotegerinIBA 09/2008
1	Matrix MetalloproteinasesIBA 01/2007
1	N- (4- ((6,7- dimethoxy- 4- quinolyl)oxy)- 2- methoxyphenyl)- N'- (1- (1,3- thiazole- 2- yl)ethyl)ureaIBA 11/2006
1	bone resorption factorIBA 08/2006
1	Carbon MonoxideIBA 05/2006
1	PhosphotyrosineIBA 05/2006
1	Transforming Growth Factor beta (TGF-beta)IBA 02/2006
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 02/2006
1	doxifluridineIBA 09/2005
1	capecitabine (Xeloda)FDA Link 09/2005
1	cimadronateIBA 02/2005
1	bone sialoproteinIBA 10/2003
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2003
1	Parathyroid Hormone-Related ProteinIBA 10/2002
1	ibandronic acid (Boniva)FDA Link 10/2002
1	Cell Adhesion MoleculesIBA 05/2002
1	Interleukin-18 (Interleukin 18)IBA 03/2002
1	platelet-derived growth factor BB (becaplermin)FDA Link 02/2002